NaTiV3 Study

Study Evaluating Long-Term Efficacy And Safety Of Lanifibranor In Adult Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (Nash) And Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage Of Liver Fibrosis

Study Purpose

The purpose of this research study is to evaluate if the study investigational medication improves your liver tissue scars (fibrosis) and resolves NASH. The study will also evaluate on the long term if the study medication can delay the complications that can ultimately damage the liver function (NASH disease progression).

Who Can Participate

Participants 18 years and older with a diagnosis of NASH may be eligible for this study.

• STUDY20211389
• NCT04849728